Searched for
INSULIN BRAND
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Novo Nordisk to phase out key drug, insulin cos spot big biz opportunityNovo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the a...
- Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brandNovo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They ...
- Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Companies like Eli Lilly, Biocon & Cadila oppose move to cut margin on insulinInsulin brands are set to appeal against the drug price regulator's decision to further squeeze their profit margins on the diabetes medici...
- Eli Lilly's imported insulin to cost same after NPPA's margin blowThe drug price regulator has halved the margin available to Eli Lilly on its imported insulin brands, effectively taking the sting out of a...
- Eli Lilly insulin brand paves way for hike in imported drug pricesThe NPPA will have to increase MRP of US firm Eli Lilly’s insulin brand, paving the way for price increases of other imported medicines who...
- Wockhardt to raise insulin prices; stock downThe drug price regulator has allowed local pharma companies Wockhardt and Biocon to increase prices of their insulin brands due to rising i...
- Wockhardt, Biocon allowed to raise Insulin prices by 18%NPPA has slashed the price of anti-asthma bulk drug used in popular brands such as Cipla's Asthalin, by 18% to Rs 3,633 per kg.
- Pharma cos to hike insulin prices by up to 15%Drug price regulator National Pharmaceutical Pricing Authority allows cos to up MRP of popular insulin brands by 15%.
- Govt slashes drug pricesThe drug price regulator National Pharmaceutical Pricing Authority has revised prices of 887 medicines, including steroids, insulin, vitami...
- Insulin prices may come down by 70 per centInsulin prices are likely to fall by up to 70 per cent as drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has bro...
- Insulin, cancer drugs will cost more soonPrices of various insulin brands and cancer drugs will soon increase while medicines for asthma, meningitis and diphtheria will become chea...
- Insulin prices to pinch less as regulator plans ceilingMore than three crore diabetics in the country can look forward to a sharp fall in human insulin prices.
- First needle-free insulin soonBiotechnology company Shreya Lifesciences has entered into an in-licensing agreement with US-based Generex Biotechnology Corp to market Ora...
Load More
